Based in Short Hills, New Jersey, Cyclacel Pharmaceuticals, Inc. (CYCC) is a clinical-stage company dedicated to the discovery, development, and commercialization of small molecule cell cycle inhibitors for the treatment of cancers and other serious disorders. The company's expertise lies in the area of Cell Cycle Inhibition which is a mechanism-targeted approach for the treatment of cancer and other serious proliferative diseases. Cyclacel aims to develop novel, cell-cycle-based mechanism-targeted cancer therapies that will stop the growth of cancer cells and will limit the damage caused to normal cells. The company's lead development candidate is a cyclin dependent kinase (CDK) inhibitor, CYC202 (seliciclib), which is in phase II trials for the treatment of non-small cell lung cancer (NSCLC). The second candidate, CYC682 (sapacitabine), is a nucleoside analog which is undergoing a randomized phase II trial in patients with advanced cutaneous T-cell lymphoma (CTCL) and another phase II trial in elderly patients with AML. The company is also developing CYC116, an Aurora kinase inhibitor, for the treatment of cancer, and initiated a phase I trial in June 2007, following submission of an investigational new drug (IND) application in December, 2006. The company has an additional eight early stage programs, which target cell cycle mechanisms for the treatment of cancer, type II diabetes, inflammatory kidney diseases, and viral infections (HIV/ AIDS). The following table summarizes the pipeline programs for the company.

Targeted Drug Pipeline

(Read more at Wikinvest )